Correction to: Drugs & Therapy Perspectives https://doi.org/10.1007/s40267-018-00596-3
Paragraph 1, Sentences 1 and 2: the following text, which previously read:
“After publication in volume 34, issue 10, pages 457–465, Ipsen Pharma requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Ipsen Pharma.”
Should read:
“After publication in volume 34, issue 10, pages 457–465, Exelixis, Inc. (Alameda, CA, USA) requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Exelixis, Inc. (Alameda, CA, USA).”
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Lyseng-Williamson, K.A. Correction to: “Correction to: Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use”. Drugs Ther Perspect 35, 200 (2019). https://doi.org/10.1007/s40267-019-00613-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-019-00613-z